Member Info for Mikemine

The CEO hit the nail on the head when he referred to large companies like Tempus not being as nimble as companies like RENX and VRCI. The take their time setting up systems and incorporating new additions and there's not much that can redone about it. Tempus will offer a reach RENX could only dream of but it comes at a price and that is a slow pace. Once the new contracts start to bear fruit ball they will gather pace and I expect that to happen early next year. Frustrating though it is for us, we will have to dig deep in to our patience bucket. Thats my opinion anyway.

I'm still waiting for the reassessment of the forecasts for sales next year due to the Tempus agreement of have i missed something?

Totally agree. Unfortunately it's very expensive to get on to NASDAQ

Marty may seem to be the most bullish poster here but I would venture that the majority of investors join him in his outlook, otherwise why are they here? There are two aspects for these small fledgling companies; survival and fulfilment of their potential. RENX has been good at surviving, to the point of commercialisation, and now it must fulfil It's potential. Thats what most of believe it can do and Marty is concentrating on that in his posts. This is not an advice BB after all so thats fair play to him. Personally, I think RENX is in with a good shout although the on costs worry me. The product is unique and needed so it should fly but we are dealing with conservative clinicians and protocols which are notoriously difficult to budge. It's a risk investment so make your own mind up which way to go or post. Good luck and carry on Marty.

I'm a bit behind the curve here Marty. Is RENX hooked up with any of this?

No. Why would they when they have a contract with a competent company that is giving them all they want with the test. Could be wrong of course but additionally RENX is just too small. That's not to say RENX is not on somebody's radar. It most definitely will be. Will come to anything? Watch this space.

Fevertreeman, your posts have got very repetitive and quite frankly, boring. Unless your rants help your mental state I for one would be grateful if you would keep your posts to new views or information.

VRCI is a small company so hiring an extra 3 salespersons is huge for them and points to their determination to hit their target. It's a big ask but you can be sure they recognise that their credibility is on the line.

From a practical point of view, hiring new salespeople takes time for their impact to come through. They have to get used of the systems, the product and VRCI's method of selling. I wish them luck and, if they do reach their target, it will be noticed by the Market.

If you think that all the tests over a broad range of conditions that clinicians use are 100% accurate 100% of the time you are sadly mistaken. You can see form Mary's post that clinicians were using an inferior test before switching to KidnetelX. Why? Because that was the best they had. KidnetelX is a proven step forward and I'm absolutely sure clinicians are welcoming it as part of their protocol. Only the conservatism of the clinicians is making this a slow sale but it is gradually being accepted and adopted by insurance companies, health authorities, hospitals and clinicians. It's painfully slow for us but we are not at the coal face and, once this gets momentum, it will gallop IMHO.

Saw this article.

https://www.gbnews.com/health/global-health-warning-chronic-kidney-disease

800 mn CKD cases worldwide. Huge market for RENX and VRCI

I strongly recommend reading carefully the CEO statement. It strikes me that RENX is where VRCI is right now. The numbers are admittedly not good and that cannot be denied but both have clear leading products in their respective fields with no visible serious competition and are offering products that the clinicians have been crying out for. Both have done the groundwork of research and have FDA approval. They are in to commercialisation and have well heeled partners. As Barrington said, "it's off to the races" Everything is in place for them to start showing vastly improved numbers in the coming year which will attract lots of attention no doubt. Neither Tempus not Thermo Fisher are known for being failures and they have both seen a chance to be front runners in these fields. They are not idiots.

If you concentrate just on the current numbers you wouldn't buy but investing is all about seeing and believing the potential. Both companies could easily be multi-baggers IMHO.

This post should not be seen as advice. It's just my opinion.

I've been thinking about the UBS movements and taking note of the info from IR of RENX. The shifting of funds around should have no effect on the SP one way or the other but the intriguing question is who is shuffling the shares and why. It seems an awful lot of shuffling and I've not seen anything like that before. Is it just a bored fund manager? It seems unlikely. Anybody got any thoughts about the II's actions?

Various organisers of Remembrance Day observances are up against Council requirements that stipulates that public liability insurance be in place for these events. In many cases that is a cost too far for organisers. Aviva is big enough to provide free insurance for these events and wouldn't the publicity be great. It probably wouldn't cost much as claims are usually minimal.

Polar Capital reduced their holding to 3.98% on the day of the announcement of the the Tempus deal. This was before the latest fundraiser so that percentage would have been reduced unless they participated in the fundraiser. Do we know if they bought more?

This is now farcical and meaningless from a news point of view.

Beats me Marty. The best thing we can do is to totally ignore any holdings RNS about UBS. Thankfully it doesn't seem to affect the SP either way.

I think the next fillip might be the revised sales estimate after accounting for Tempus's likely uplift in sales. Depends when they get their sales guys to start pushing the test I suppose.

Tempus is, with its SP, in a favoured light and probably rightly so. The danger for it is the questioning of AI by the investment community. When/if the AI bubble bursts it might be taken down with it. It shouldn't be but I don't have that much faith in investor, retail and institutional, ability to see the good ones apart from the bad ones. As for RENX, it should be more seen as a research, and now a commercial, company that is using AI and genuine discoveries delivering a leap forward in kidney disease prediction. It is well under appreciated by the investment community IMHO.

Still don't understand it with UBS. I can't recollect anything like it before.

MMs, quick to drop the SP and reluctant to raise it.